Velentzis LS et al. – HPV screening in populations with high vaccination coverage, beginning at 25 years of age, decreases the risk of cervical cancer and excisional treatment.

Methods

• The cumulative lifetime risk (CLR) of cervical cancer and excisional treatment; and change in adverse obstetric outcomes in HPV unvaccinated women and cohorts offered vaccination (>70% coverage) was determined. 2-yearly cytology screening (18-69 years of age) was compared to 5-yearly primary HPV screening with partial genotyping for HPV16/18 (25-74 years of age).

Results

• With cytology screening, the CLR of cervical cancer diagnosis, death, and treatment would be 0.65%, 0.20%, and 13% without vaccination and 0.18%, 0.06% and 7%, in vaccinated cohorts, respectively.
• With HPV screening, relative reductions of 33% and 22% in cancer risk for unvaccinated and vaccinated cohorts were predicted, respectively, compared to cytology screening.
• Without vaccination, a 4% increase in treatment risk for HPV versus cytology screening was predicted.
• In vaccinated cohorts treatment risk will decrease by 13%.